ZYNE - Zynerba Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Delayed price. Currency in USD
11.50
+0.25 (+2.22%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close11.25
Open11.27
Bid0.00 x 0
Ask0.00 x 0
Day's range11.05 - 11.58
52-week range5.42 - 25.95
Volume200,164
Avg. volume410,704
Market cap155.87M
BetaN/A
PE ratio (TTM)N/A
EPS (TTM)-2.57
Earnings date9 Aug 2017 - 14 Aug 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.40
Trade prices are not sourced from all markets
  • Globe Newswire14 days ago

    Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update

    DEVON, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) --  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced that it will concentrate its focus on rare (meeting the US FDA designation of an orphan disease, affecting fewer than 200,000 people in the U.S.) and near-rare (affecting fewer than one million people in the U.S.) neurological and psychiatric (“neuropsychiatric”) disorders with high unmet medical needs. In 2018, the Company intends to develop ZYN002 in a pivotal Phase 2/3 program in Fragile X syndrome (FXS) and in Phase 2 programs in refractory epilepsies, including adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE) in pediatric and adolescent patients.

  • Can This Beaten-Down Marijuana Stock Roar Back in 2018?
    Motley Fool26 days ago

    Can This Beaten-Down Marijuana Stock Roar Back in 2018?

    Zynerba faces some big questions heading into the new year.

  • Canada’s Cannabis Market Could Be About To Explode
    Oilprice.comlast month

    Canada’s Cannabis Market Could Be About To Explode

    Experts expect a serious cannabis shortage as Canada looks to legalize recreational cannabis in 2018, creating huge opportunities for savvy investors

  • Associated Press2 months ago

    Zynerba reports 3Q loss

    On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 63 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • 3 Marijuana Stocks That Like to Live Life Dangerously
    Motley Fool3 months ago

    3 Marijuana Stocks That Like to Live Life Dangerously

    Whether it's a single-drug portfolio or little cash on hand, these drug developers are the definition of risk.

  • Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
    Zacks4 months ago

    Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

    Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes